Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30420419 | 0.82 | SMN1; SMN2 (0.72) | TSHRSMN1; SMN2TDP1GAAL3MBTL1 | |
| SCHEMBL14515451 | 0.82 | CYP2C9 (0.59) | TSHRSMN1; SMN2TDP1GAAL3MBTL1 | |
| SCHEMBL6442338 | 0.82 | SMN1; SMN2 (0.72) | TSHRSMN1; SMN2TDP1GAAL3MBTL1 | |
| SCHEMBL24715738 | 0.81 | MEN1 (0.62) | TSHRL3MBTL1KMT2AMEN1ALDH1A1 | |
| SCHEMBL862532 | 0.80 | TSHR (0.70) | TSHRSMN1; SMN2TDP1GAAL3MBTL1 | |
| SCHEMBL10684407 | 0.80 | SMN1; SMN2 (0.68) | TSHRSMN1; SMN2TDP1GAAL3MBTL1 | |
| SCHEMBL7932275 | 0.80 | SMN1; SMN2 (0.68) | TSHRSMN1; SMN2TDP1GAAL3MBTL1 | |
| SCHEMBL9573422 | 0.79 | SMN1; SMN2 (0.63) | TSHRSMN1; SMN2TDP1GAAL3MBTL1 | |
| SCHEMBL10061803 | 0.78 | SMN1; SMN2 (0.61) | TSHRSMN1; SMN2TDP1GAAL3MBTL1 | |
| SCHEMBL7821283 | 0.77 | TSHR (0.71) | TSHRSMN1; SMN2TDP1GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4623914-A1 | USE OF 8-HYDROXYQUINOLINE DERIVATIVE | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2025-10-01 | — | — | EP | disclosed |
| US-20240246916-A1 | 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVES, PREPARATION METHOD THEREFORE AND MEDICAL USE THEREOF | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2024-07-25 | — | — | US | disclosed |
| WO-2024109684-A1 | USE OF 8-HYDROXYQUINOLINE DERIVATIVE | 江苏亚虹医药科技股份有限公司 | 2024-05-30 | — | — | WO | disclosed |
| EP-4349815-A1 | 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2024-04-10 | — | — | EP | disclosed |
| WO-2022253152-A1 | 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253152-A1 | 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246916-A1 | 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVES, PREPARATION METHOD THEREFORE AND MEDICAL USE THEREOF | CYP3A7, UGT1A7, UGT2B7 | TSHR 4796/4885SMN1; SMN2 3763/4885TDP1 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.